Irinotecan Vista for infusions 20 mg/ml. 5 ml/100 mg. vial

$180.00

Manufacturer: Italy

Category:

Description

Treatment of patients with advanced colorectal cancer: in combination with 5-fluorouracil and folic acid, when previous chemotherapy for the treatment of a common disease was not used; as monotherapy, when the established treatment regimen using 5-fluorouracil was ineffective. In combination with cetuximab, Irinotecan is used to treat metastatic colorectal cancer with a wild type of KRAS gene that expresses receptors for epidermal growth factor in patients who have not previously received treatment for metastatic cancer or for whom cytotoxic treatment with irinotecan has proved ineffective. In combination with 5-fluorouracil, folinic acid and bevacizumab, Irinotecan is used as a first-line therapy for patients with metastatic carcinomas of the colon or rectum. In combination with capecitabine (with or without bevacizumab), Irinotecan is used as a first-line therapy for patients with metastatic colorectal cancer.